Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
AI Pharmaceutical Company Jitai Technology Launches IPO, Plans to List on the Hong Kong Stock Exchange
Mars Finance News: On May 5, it was announced that Ji Tai Technology (METiS) will conduct a public offering from May 5 to May 8, planning to issue approximately 201 million H shares. The offering price is HKD 10.50 per share, and the company is expected to list on May 13 under the code “7666.” This IPO brings in 18 cornerstone investors, with a total subscription of $148 million. The roster includes international institutions such as BlackRock, UBS, and Korea Future Asset, as well as state-owned funds and leading private equity firms such as Guofeng Investment Fund, Hillhouse, and IDG. Excluding the greenshoe mechanism, the fund-raising scale exceeds HKD 2.1 billion.
The company operates based on its AI nano-delivery platform NanoForge, and has applied for a total of 224 patents. In 2025, revenue is expected to reach 1.05 billion yuan, up significantly from 1.5 million yuan in 2024. The gross profit margin has increased from 55.5% to 98.2%, and losses during the year have narrowed to 392 million yuan. The company currently holds cash and cash equivalents of 1.13 billion yuan. Its core pipeline, MTS-004, has entered Phase III clinical trials, and the company plans to allocate 50% of the funds raised to research and development of the AI platform. (Kebao Broadcast)